BeiGene Ltd ADR (NASDAQ: BGNE) on Monday, soared 5.31% from the previous trading day, before settling in for the closing price of $233.64. Within the past 52 weeks, BGNE’s price has moved between $126.97 and $238.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 92.60% over the past five years. The company achieved an average annual earnings per share of 35.44%. With a float of $96.46 million, this company’s outstanding shares have now reached $97.34 million.
Let’s look at the performance matrix of the company that is accounted for 10000 employees.
BeiGene Ltd ADR (BGNE) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BeiGene Ltd ADR is 0.90%, while institutional ownership is 47.39%. The most recent insider transaction that took place on Sep 30 ’24, was worth 284,994. In this transaction SVP, General Counsel of this company sold 1,202 shares at a rate of $237.10, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 27 ’24, when Company’s Global Head of R&D sold 5,000 for $220.35, making the entire transaction worth $1,101,774. This insider now owns 0 shares in total.
BeiGene Ltd ADR (BGNE) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 35.44% per share during the next fiscal year.
BeiGene Ltd ADR (NASDAQ: BGNE) Trading Performance Indicators
BeiGene Ltd ADR (BGNE) is currently performing well based on its current performance indicators. A quick ratio of 1.75 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.08, a number that is poised to hit -1.56 in the next quarter and is forecasted to reach -0.82 in one year’s time.
Technical Analysis of BeiGene Ltd ADR (BGNE)
BeiGene Ltd ADR (NASDAQ: BGNE) saw its 5-day average volume 0.43 million, a positive change from its year-to-date volume of 0.25 million. As of the previous 9 days, the stock’s Stochastic %D was 89.49%. Additionally, its Average True Range was 8.36.
During the past 100 days, BeiGene Ltd ADR’s (BGNE) raw stochastic average was set at 98.02%, which indicates a significant increase from 95.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.91% in the past 14 days, which was lower than the 40.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $194.62, while its 200-day Moving Average is $167.10. Nevertheless, the first resistance level for the watch stands at $248.45 in the near term. At $250.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $253.55. If the price goes on to break the first support level at $243.35, it is likely to go to the next support level at $240.65. Assuming the price breaks the second support level, the third support level stands at $238.25.
BeiGene Ltd ADR (NASDAQ: BGNE) Key Stats
Market capitalization of the company is 23.95 billion based on 96,903K outstanding shares. Right now, sales total 2,459 M and income totals -881,710 K. The company made 929,170 K in profit during its latest quarter, and -120,410 K in sales during its previous quarter.
